A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
-
Adult
-
Adult
-
Aged
-
Aged
-
Aged, 80 and over
-
Aged, 80 and over
-
CA-125 Antigen
-
CA-125 Antigen
-
Disease Progression
-
Disease Progression
-
Disease-Free Survival
-
Disease-Free Survival
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Fallopian Tube Neoplasms
-
Fallopian Tube Neoplasms
-
Female
-
Female
-
Humans
-
Humans
-
Injections, Subcutaneous
-
Injections, Subcutaneous
-
Middle Aged
-
Middle Aged
-
Ovarian Neoplasms
-
Ovarian Neoplasms
-
Peptide Fragments
-
Peptide Fragments
-
Peritoneal Neoplasms
-
Peritoneal Neoplasms
-
Placebos
-
Placebos
-
Prospective Studies
-
Prospective Studies
-
Receptors, Cell Surface
-
Receptors, Cell Surface
-
Receptors, Urokinase Plasminogen Activator
-
Receptors, Urokinase Plasminogen Activator
-
Urokinase-Type Plasminogen Activator
-
Urokinase-Type Plasminogen Activator